Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The Further In You Go, The Bigger It Gets | Main | Everything In Its Place »

July 17, 2009

Drug Approvals, Natural And Unnatural

Email This Entry

Posted by Derek

I seem to have been putting a lot of graphics up this week, so here's another one. This is borrowed from a recent Science paper on the future of natural-products based drug discovery. It's interesting both from that viewpoint, and because of the general approval numbers:
Nat%20Prod%20drugs%20and%20approvals%20graph.jpg
And there you have it. Outside of anomalies like 2005, we can say, I think, that the 1980s were a comparative Golden Age of Drug Approvals, that the 1990s held their own but did not reach the earlier heights, and that since 2000 the trend has been dire. If you want some numbers to confirm your intuitions, you can just refer back to this.

As far as natural products go, from what I can see, the percentage of drugs derived from them has remained roughly constant: about half. Looking at the current clinical trial environment, though, the authors see this as likely to decline, and wonder if this is justified or not. They blame two broad factors, one of them being the prevailing drug discovery culture:

The double-digit yearly sales growth that drug companies typically enjoyed until about 10 years ago has led to unrealistically high expectations by their shareholders and great pressure to produce "blockbuster drugs" with more than $1 billion in annual sales (3). In the blockbuster model, a few drugs make the bulk of the profit. For example, eight products accounted for 58% of Pfizer’s annual worldwide sales of $44 billion in 2007.

As an aside, I understand the problems with swinging for the fences all the time, but I don't see the Pfizer situation above as anything anomalous. That's a power-law distribution, and sales figures are exactly where you'd expect to see such a thing. A large drug company with its revenues evenly divided out among a group of compounds would be the exception, wouldn't it?

The other factor that they say has been holding things back is the difficulty of screening and working with many natural products, especially now that we've found many of the obvious candidates. A lot of hits from cultures and extracts are due to compounds that you already know about. The authors suggest that new screening approaches could get around this problem, as well as extending the hunt to organisms that don't respond well to traditional culture techniques.

None of these sound like they're going to fix things in the near term, but I don't think that the industry as a whole has any near-term fixes. But since the same techniques used to isolate and work with tricky natural product structures will be able to help out in other areas, too, I wish the people working on them luck.

Comments (10) + TrackBacks (0) | Category: Business and Markets | Drug Assays | Drug Development | Drug Industry History


COMMENTS

1. JAB on July 17, 2009 10:34 AM writes...

Thanks! (for wishing us luck)

Permalink to Comment

2. bad wolf on July 17, 2009 2:35 PM writes...

I would also expect the proportion of NP to decline, now that big pharma have mostly fired their NP isolation and characterization teams.

Permalink to Comment

3. Curious Wavefunction on July 17, 2009 4:49 PM writes...

What next? Natural products from mammals? I do think that some of the big critters are underexploited. Think of Jerry Meinwald and his insect and spider extractions. However I don't expect to live long enough to see Merck advertising for an Arachnid Natural Products Extraction Specialist.

Permalink to Comment

4. Morten G on July 17, 2009 7:28 PM writes...

Finally! A graphic I can read.

Permalink to Comment

5. Chemjobber on July 17, 2009 10:48 PM writes...

@CW: I don't know about that -- they're advertising for a Research Fellow in Particle Sizing, so Arachnid Extraction Specialist can't be far behind.

(I know, I know, formulating is important...)

Permalink to Comment

6. David Kroll on July 18, 2009 8:01 AM writes...

Thanks very much for the insights on this very interesting paper.

I do have a question for you: as an academician who interacts somewhat with pharma colleagues, it seems as though industrial interest in natural products has waned. Several well-known pharma natural products discovery units have been shuttered over the last few years (although many unrelated pharma programs have suffered similarly, so I don't know if natural products is being hit disproportionately.).

Assuming that commercial entities are less interested in natural products discovery, how do you and/or your pharma commenters view the value of academic natural products discovery researchers in contributing to the generation of new leads? Or am I just not privy to robust natural products efforts ongoing in the industry?

Permalink to Comment

7. NP advocate on July 19, 2009 1:48 PM writes...

As Derek pointed out "the percentage of drugs derived from Natural Products has remained roughly constant: about half." Now, let me remind you that nearly all Big Pharma have shut down their NP units over the past 15 years. Resources were diverted to other ventures which proved for the most part to be a total waste (remember CombiChem?). Therefore, the current level of NPs & naturally inspired new drugs (ca. 50%) does not tell the whole story. When properly adjusted for the massive cuts of NP programs, it actually represents a sharp increase over the past few years.

Permalink to Comment

8. Doctor Doom on July 19, 2009 3:02 PM writes...

It would be more interesting to see the graphs adjusted to remove antibiotics. My impression is that once you remove those from the equation there are far fewer that are natural product derived although there a few interesting exceptions. To answer David Kroll, I don't think industry as a whole particularly values any academic drug discovery research, NP or otherwise. At conferences, when an academic drug discovery worker stands up to speak, we nip out and grab a coffee. Why ? Because I 've met very few who actually have any concept of what real drug discovery is about and the huge variety of issues that need to be addressed and balanced. NPs are out of favour because they are a great wait of wasting vast amounts of manpower for no result. Now I'm not going to defend the early days of combichem either, but done properly, it can be a good way of generating leads for new targets and I can think of many, many programmmes where they have been the main source of leads and ultimately development compounds. So I don't hink it is a lack of leads that is messing up the industry right now, more a case of "the talent" leading us in the wrong direction.

Permalink to Comment

9. Ty on July 19, 2009 9:11 PM writes...

I don't know how you count the NP-derived drugs. Do you count the 'biomimetic' drugs like beta-lactams, steroids, sugars, monoamines, etc? Structurally, they are NP-derived, all right, but were they really found in the NP research context? Well, I didn't think so either. Antibiotics are a different story. People are still (or even more than ever) valuing NPs in the antibacterial research. Now, if you leave these two classes out, maybe it's just me, but I don't see as many 'NP-derived' drugs as others do.


Permalink to Comment

10. Allen on July 28, 2009 9:07 PM writes...

This all comes down to developability. We need drugs with better PK/PD and physical properties. In my opinion the fail rate could be level set at a much better level.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Molecular Printing of Drug Molecules. Say What?
Pfizer Walks Again By Night
Gitcher SF5 Groups Right Here
Changing A Broken Science System
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi